ISAD Events platform

Welcome to Doha!

Doha 2024
Georg RAJKA — ISAD
Sheraton Al Majlis
October 24~26, 2024

Poster session 1 on Oct. 24th — from 15:45 to 16:30
Screen	Time	#ref	Author & title
Moderator: Akihiko IKOMA, Japan
A	15:30	#761	Robin ROHAYEM Effect of a skin pH reducing emollient on the skin microbiome in the context of atopic dermatitis
	15:39	#438	Febu JOYQuality of Life in Adult Patients with Atopic Dermatitis in Qatar
	15:48	#425<48d>	Roberto TAKAOKA Atopic Dermatitis Patient’s Journey through the Healthcare System in Brazil
	15:57	#538	Robin ROHAYEM Topical and systemic immunomodulatory therapies and the skin microbiome in atopic dermatitis: A pilot study from the CK-Care ProRaD cohort
	16:06	#411	Amina Nomtondo OUEDRAOGO Direct medical cost of emollients in the management of atopic dermatitis in Ouagadougou
Moderator:
B	15:30	#426	Zobiri SAMIRA Therapeutic education in atopic dermatitis: an observational study
	15:39	#405	Hye-One KIM Analysis of Skin Microbiota and Tryptophan Metabolites in Children with Atopic Dermatitis
	15:48	#362	Naoko HATTORI Delayed blanch Phenomenon to Acetylcholine and Its Association with Sweating Function in Atopic Dermatitis: A Case Study
	15:57	#465	Bérénice DEGBOE Atopic dermatitis in adults : clinical forms and associated comorbidities from 2019-2023 in the University Clinic of Dermatology-Venerology of NUHC-HKM, Cotonou (Benin)
	16:06	#534	William Wael JEBRIL Individuals with Darier disease have an increased risk of suicide and self-injurious behaviours
Moderator: Dirk JAN HIJNEN, Netherlands
C	15:30	#392	Young Bok LEE Transcriptomic Insights into Prurigo Nodularis: Unraveling Neuronal Profiles and Immune Response
	15:39	#490	Alain TAÏEB Moisturizers for Atopic Dermatitis (AD): the ISAD-WHO application to include registered creams in the core list of the essential medicines’ lists (EML and EMLc).
	15:48	#400	Jiehyun JEON Disease Modification of Methotrexate in Atopic Dermatitis with Decreasing Eosinophils and Specific Immunoglobulin E - Pilot Study
	15:57	#368	Chang Ook PARK The Future of Atopic Dermatitis Care: Defining Endophenotypes and Exploring Biomarkers for precision medicine
	16:06	#415	Mohammed Nasser AL-ABDULLA Successful treatment of Prurigo Nodularis in a Pediatric Patient using anti-Il-4 receptor-A antibody Dupilumab
Moderator: Medhat ASKAR, Qatar
D	15:30	#395	Celestin Kouadio AHOGO Atopy School: First experience in French-speaking Sub-Saharan Africa, Acquisitions, challenges and outlook
	15:39	#369	Yu Ri WOO Differential expression of antimicrobial peptides in scalp dermatitis among patients with atopic dermatitis
	15:48	#559	Abdul Mannan MUSTAFA Knowledge, attitude and practices of Primary healthcare providers reagarding Atopic Dermatitis in Multan, Pakistan
	15:57	#366	Sailan WANG Investigating the role of the FLG2 gene in Atopic Dermatitis in the Swedish population
	16:06	#452	Ga-Young LEE The Correlation between EASI Score and Multiple Allergen Simultaneous Test (MAST) Results in Atopic Dermatitis Patients
Moderator: Majid Ali ALAM, Qatar
E	15:30	#332	Kiran GODSE Atopic dermatitis in Indian skin
	15:39	#387	Tsiory Iarintsoa RAZAFIMAHARO Association between atopic dermatitis and leprosy
	15:48	#319	Sinu Rose MATHACHAN The prevalence and severity of atopic dermatitis and the pattern of pediatric dermatoses: A six-month study from a multispecialty clinic in Dubai, UAE
	15:57	#322	Fatimh Hussain ALMARRI Topical Corticosteroid Phobia Among Caregivers Of Children With Atopic Dermatitis: A Cross-Sectional Study Using TOPICOP Score In Saudi Arabia
	16:06	#357	Yousef DASHTI The microbiome in inflammatory skin disorders: The Inner Workings of The Outer Surface
Poster session 2 on Oct. 25th — from 09:30 to 10:00
Screen	Time	#ref	Author & title
Moderator: Arturo BORZUTZKY, Chile
A	09:30	#402	Weronika ZYSK Can we predict dupilumab treatment outcomes in adult patients with atopic dermatitis? A retrospective single-center study
	09:39	#333	Delphine STAUMONT-SALLÉ Switching from Dupilumab to Tralokinumab or JAK inhibitors in cases of ocular and/or facial adverse events: a real-life experience
	09:48	#774	Martin DOSSENBACK Lebrikizumab versus Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: A Network Meta-analysis of Short-term Efficacy
Moderator: Akihiko IKOMA, Japan
B	09:30	#399	Hye-One KIM Comparison of Skin Transcriptomes from Biopsies in Prurigo Patients with and without Atopic Dermatitis
	09:39	#446	Mike BASTIAN Optimal itch response with dupilumab irrespective of EASI outcome in adult patients with moderate-to-severe AD
	09:48	#461	Yoko KATAOKA Abnormally elevated serum TARC may predict secondary ineffectiveness of systemic JAK inhibitors
Moderator: Sébastien BARBAROT, France
C	09:30	#434	Fengxian LI A topical Chinese herbal inhibits pruritus and skin inflammation via neural TRPM8 in atopic dermatitis
	09:39	#344	Brad WOODIE Compared with dupilumab non-prescribers, dupilumab prescribers practice more evidence-based guideline care: fewer prescribed days of systemic corticosteroids and more days of topical corticosteroid-sparing agents
	09:48	#769	Magdalena TRZECIAK Contact sensitization to topical medications in patients with symptoms of allergic contact dermatitis, with and without atopic dermatitis - a 10-year retrospective analysis of patch test results
Moderator: Georg STINGL, Austria
D	09:30	#299	Mutong ZHAO Upadacitinib for Refractory Pediatric Atopic Dermatitis: A Real-World Study on Effectiveness and Safety in Dupilumab Non-Responders
	09:39	#373	Seong Jun SEO Effectiveness of Non-Live Recombinant Herpes Zoster Vaccine in Reducing Herpes Simplex Virus Reactivation in Atopic Dermatitis Patients Treated with Janus Kinase Inhibitors
	09:48	#333	Delphine STAUMONT-SALLÉ Switching from Dupilumab to Tralokinumab or JAK inhibitors in cases of ocular and/or facial adverse events: a real-life experience
Moderator: Kiran GODSE, India
E	09:30	#356	Yousef DASHTI Complications of Dupilumab Therapy: A Literature Review of Side Effects and Clinical Case Report of Renal Adverse Event
	09:39	#335	Andreas WOLLENBERG Improvements in itch and sleep disturbance are maintained up to Week 48 with nemolizumab plus TCS/TCI treatment in patients with moderate-to-severe atopic dermatitis: Results from two global phase 3 pivotal studies (ARCADIA 1 and ARCADIA 2)
	09:48	#485	Park SU JUNG Is Eczema Area and Severity Index score ³23 a suitable cut-off for severe atopic dermatitis?
Poster session 3 on Oct. 25th — from 15:15 to 16:00
Screen	Time	#ref	Author & title
Moderator: Kiran GODSE, India
A	15:15	#458	Florine MANJARIMANANA Treatment satisfaction of parents of children with atopic dermatitis treated with dermocorticoids
	15:24	#462	Wei LI Abrocitinib rapidly and extensively normalizes dysregulated blood transcriptome of atopic dermatitis patients
	15:33	#PSG	Peter SCHMID-GRENDELMEIER Allergic contact dermatitis due to hair adhesives
	15:42	#766	Gloria Elisante MASENGA Quality of life among adult atopic dermatitis patients attending the regional dermatology training center in Northern Tanzania
Moderator: Majid Ali ALAM, Qatar
B	15:15	#303	Atsushi OTSUKA Effectiveness and Safety of Nemolizumab in Treating Atopic Dermatitis Among Japanese Patients: A Retrospective Study at a Single Center
	15:24	#407	Sun Young CHOI Ameliorative effects of escin on inflammation via Glucocorticoid Receptor in atopic dermatitis mouse model
	15:33	#385	Xiaoyan LUO Sixteen-Week Dupilumab Therapy Fails to Normalize Systemic Type 2 Inflammation in Children Under 6 Years with Moderate-to-Severe Atopic Dermatitis: A Real-world Cohort Study
	15:42	#763	Sang Eun LEE Distinct transcriptomic profiles of sensory neurons in mouse model of atopic dermatitis and psoriasis: insight into the mechanism of chronic itch in atopic dermatitis and psoriasis
Moderator: Akihiko IKOMA, Japan
C	15:15	#457	Ana B. ROSSI Dupilumab Monotherapy Prevents Flares and Provides Sustained Control of Atopic Dermatitis Over 1 Year Across Various Dosing Frequencies
	15:24	#379	Carsten FLOHR Living network meta-analysis of systemic treatments for atopic dermatitis
	15:33	#397	Thomas BIEBER Maintenance of Optimal Response Over 2 Years in Patients With Atopic Dermatitis Treated With Dupilumab
	15:42	#767	Arturo BORZUTZKY Lipidomics of vernix caseosa is modified by maternal overweight/obesity and associates with development of atopic dermatitis in the offspring
Moderator: Alain TAÏEB, France
D	15:15	#454	Andreas WOLLENBERG Treatment with tralokinumab provides long-term control of head and neck atopic dermatitis
	15:24	#439	Annie ZHANG Real-World treatment outcomes of systemic treatments for moderate-to-severe atopic dermatitis in children aged less than 12 years: 4-year results from the PEDISTAD Registry
	15:33	#422	Pontus Olov Allan JONSSON Drug survival of systemic treatments for atopic dermatitis in Sweden
	15:42	#651	Erere OTROFANOWEI Clinical and biophysical parameters of patients with Atopic Dermatitis in Nigeria and correlation with disease severity
Moderator: Georg STINGL, Austria
E	15:15	#343	Mahsa TAYEFI Body weight and tryptophan/kynurenine metabolites during treatment with dupilumab
	15:24	#405	Hye-One KIM Analysis of Skin Microbiota and Tryptophan Metabolites in Children with Atopic Dermatitis
	15:33	#325	Hyounchang KO Oral cyclosporine for pediatric atopic dermatitis: A real-world experience of efficacy and safety
	15:42	#386	Justyna SZCZĘCH TADPol study: a real-world evidence on dupilumab and upadacitinib in the treatment of moderate-to-severe atopic dermatitis in Poland
Poster session 4 on Oct. 26th — from 10:35 to 11:00
Screen	Time	#ref	Author & title
Moderator: Kiran GODSE, India
A	10:35	#430	Jensen YEUNG Clinical adverse events with upadacitinib in adolescent and adult patients with atopic dermatitis: interim analysis of a real-world multicentre retrospective review
	10:44	#355	Mike BASTIAN Understanding the Patient’s Perception: Which EASI Threshold is Clinically Meaningful to Patients With Atopic Dermatitis?
	10:53	#441	Annie ZHANG Growth Analysis at Baseline in Children and Adolescents With Moderate-to-Severe Atopic Dermatitis Enrolled in Phase 3 Dupilumab Trials
Moderator: Georg STINGL, Austria
B	10:35	#432	Neal KOLLER Itch Reduction and Quality of Life Improvement in AD for First Human Use of Zabalfin
	10:44	#762	Erere OTROFANOWEI Sensitization to mites and cockroaches is highly predominant in atopic dermatitis patients in Nigeria - a pilot study from Lagos
	10:53	#364	Eung Ho CHOI Analysis of Patch Test Results Focusing on Atopic History in Rosacea Patients: A Retrospective Study
Moderator: Majid Ali ALAM, Qatar
C	10:35	#367	Chia-Yu CHU Disease burden and treatment preference for moderate-to-severe atopic dermatitis in Taiwan: a discrete-choice experiment
	10:44	#428	Roberto TAKAOKA Creating a Model for Evaluating Healthcare Disparities in the Accessibility of Treatments for Atopic Dermatitis
	10:53	#380	Ana B. ROSSI Dupilumab Improves Quality of Life in Patients With Atopic Hand and/or Foot Dermatitis
Moderator: Akihiko IKOMA, Japan
D	10:35	#371	Byeol HAN Real-world Prevalence and Associated Factors of Nipple Eczema in Patients with Atopic Dermatitis
	10:44	#436	Annie ZHANG Impact of Dupilumab Treatment on Seasonal Disease Severity in Adults With Moderate-to-Severe Atopic Dermatitis
	10:53	#427	Amina Nomtondo OUEDRAOGO Knowledge attitudes practices of atopic patients in Ouagadougou
Moderator: Fang WANG, China
E	10:35	#378	Carsten FLOHR The Global Atopic Dermatitis Atlas: A Systematic Review Mapping Global Burden of Atopic Dermatitis
	10:44	#414	John C. SU Identifying risk factors related to social disadvantage in atopic dermatitis patients who are referred to an Australian paediatric tertiary referral centre
	10:53	#365	Dong hun LEE Early-life dietary factors and risk of persistent atopic dermatitis: A nationwide cohort and cross-sectional study
Poster session 5 on Oct. 26th — from 15:20 to 16:00
Screen	Time	#ref	Author & title
Moderator: Georg STINGL, Austria
A	15:20	#396	Annie ZHANG Dupilumab reduces lesion severity and extent in children <12 years of age with moderate-to-severe AD: interim results from the PEDISTAD real-world registry
	15:29	#377	Shin MIN-KYUNG Classification of facial involvement in atopic dermatitis
	15:38	#381	Fenohasina RAKOTONANDRASANA Association of Tralokinumab and Adalimumab: Good tolerance and efficacy in a case of severe atopic dermatitis and juvenile idiopathic arthritis
	15:47	#773	Thomas BIEBER EASI 90 Response Sustained up to 38 Weeks After Lebrikizumab Withdrawal Despite Negligible Serum Concentrations
Moderator: Akihiko IKOMA, Japan
B	15:20	#320	Shan WANG Real-World Treatment Outcomes of Dupilumab and Baseline Health Economic Burden in Children and Adolescents with Moderate-to-Severe Atopic Dermatitis: Results from the ADOPED-STAD Study in China
	15:29	#460	Wei LI Temporal and topographical heterogeneities in clinical manifestations of atopic dermatitis revealed by a non-selective registry in China
	15:38	#661	Xin Yi N Exploring the link between Mind and Skin: understanding the neurocutaneous axis in atopic dermatitis
Moderator: Kiran GODSE, India
C	15:20	#376	John CHITTOCK Optical Coherence Tomography Differentiates Skin Atrophogenicity of Topical Anti-inflammatory Treatments in Patients With Atopic Dermatitis
	15:29	#449	John C. SU Dupilumab Efficacy and Safety up to 2 Years in Children Aged 6 Months to 5 Years With Moderate-to-Severe Atopic Dermatitis
	15:38	#330	Pranvera SULEJMANI The Global Reach of Artificial Intelligence in Atopic Dermatitis
	Moderator: Majid Ali ALAM, Qatar
D	15:20	#337	Yi Na YOON Dupilumab Associated Head and Neck Dermatitis with Conjunctivitis: A Case Series
	15:29	#431	Vimal H. PRAJAPATI Use of systemic Janus kinase inhibitors for pediatric atopic dermatitis: a systematic review of randomized controlled trials

2025-05-09 09:00:19

Array
(
    [1] => en
    [2] => event
    [3] => rajka-2024-isad-doha
    [4] => posters
)

array(4) {
  [0]=>
  array(4) {
    ["file"]=>
    string(100) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/view/common/debug.php"
    ["line"]=>
    int(37)
    ["function"]=>
    string(1) "p"
    ["args"]=>
    array(1) {
      [0]=>
      array(4) {
        [1]=>
        string(2) "en"
        [2]=>
        string(5) "event"
        [3]=>
        string(20) "rajka-2024-isad-doha"
        [4]=>
        string(7) "posters"
      }
    }
  }
  [1]=>
  array(4) {
    ["file"]=>
    string(103) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/view/template_public.php"
    ["line"]=>
    int(179)
    ["args"]=>
    array(1) {
      [0]=>
      string(100) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/view/common/debug.php"
    }
    ["function"]=>
    string(12) "require_once"
  }
  [2]=>
  array(4) {
    ["file"]=>
    string(87) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/main.php"
    ["line"]=>
    int(131)
    ["args"]=>
    array(1) {
      [0]=>
      string(103) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/view/template_public.php"
    }
    ["function"]=>
    string(12) "require_once"
  }
  [3]=>
  array(4) {
    ["file"]=>
    string(91) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/public/index.php"
    ["line"]=>
    int(21)
    ["args"]=>
    array(1) {
      [0]=>
      string(87) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/main.php"
    }
    ["function"]=>
    string(12) "require_once"
  }
}

2025-05-09 09:00:19

Array
(
    [co] => 0
    [co_type] => noco
    [csrf] => 53da535775b95c7fbe6639674ab938805c9bba92232b0bc25c3f0a2ac0910505
    [type] => pblc
    [ip] => Array
        (
            [0] => 82.64.105.170
        )

    [rank] => 0
    [anonymize] => 0
)

array(4) {
  [0]=>
  array(4) {
    ["file"]=>
    string(100) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/view/common/debug.php"
    ["line"]=>
    int(37)
    ["function"]=>
    string(1) "p"
    ["args"]=>
    array(1) {
      [0]=>
      array(7) {
        ["co"]=>
        int(0)
        ["co_type"]=>
        string(4) "noco"
        ["csrf"]=>
        string(64) "53da535775b95c7fbe6639674ab938805c9bba92232b0bc25c3f0a2ac0910505"
        ["type"]=>
        string(4) "pblc"
        ["ip"]=>
        array(1) {
          [0]=>
          string(13) "82.64.105.170"
        }
        ["rank"]=>
        string(1) "0"
        ["anonymize"]=>
        string(1) "0"
      }
    }
  }
  [1]=>
  array(4) {
    ["file"]=>
    string(103) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/view/template_public.php"
    ["line"]=>
    int(179)
    ["args"]=>
    array(1) {
      [0]=>
      string(100) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/view/common/debug.php"
    }
    ["function"]=>
    string(12) "require_once"
  }
  [2]=>
  array(4) {
    ["file"]=>
    string(87) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/main.php"
    ["line"]=>
    int(131)
    ["args"]=>
    array(1) {
      [0]=>
      string(103) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/view/template_public.php"
    }
    ["function"]=>
    string(12) "require_once"
  }
  [3]=>
  array(4) {
    ["file"]=>
    string(91) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/public/index.php"
    ["line"]=>
    int(21)
    ["args"]=>
    array(1) {
      [0]=>
      string(87) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/main.php"
    }
    ["function"]=>
    string(12) "require_once"
  }
}

2025-05-09 09:00:19

Array
(
    [active] => 0
    [role] => Array
        (
            [job] => 0
        )

    [geo] => Array
        (
            [country] => 0
        )

    [asso] => Array
        (
            [membership] => 0
        )

    [mail] => Array
        (
            [optin] => 0
        )

    [avatar] => default.png
    [review] => Array
        (
        )

    [theme] =>  class="brand"
    [logo] => logo-typo.svg
    [theme_id] => 1
    [body_class] => event
)

array(4) {
  [0]=>
  array(4) {
    ["file"]=>
    string(100) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/view/common/debug.php"
    ["line"]=>
    int(37)
    ["function"]=>
    string(1) "p"
    ["args"]=>
    array(1) {
      [0]=>
      array(11) {
        ["active"]=>
        int(0)
        ["role"]=>
        array(1) {
          ["job"]=>
          int(0)
        }
        ["geo"]=>
        array(1) {
          ["country"]=>
          int(0)
        }
        ["asso"]=>
        array(1) {
          ["membership"]=>
          int(0)
        }
        ["mail"]=>
        array(1) {
          ["optin"]=>
          int(0)
        }
        ["avatar"]=>
        string(11) "default.png"
        ["review"]=>
        array(0) {
        }
        ["theme"]=>
        string(14) " class="brand""
        ["logo"]=>
        string(13) "logo-typo.svg"
        ["theme_id"]=>
        int(1)
        ["body_class"]=>
        string(5) "event"
      }
    }
  }
  [1]=>
  array(4) {
    ["file"]=>
    string(103) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/view/template_public.php"
    ["line"]=>
    int(179)
    ["args"]=>
    array(1) {
      [0]=>
      string(100) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/view/common/debug.php"
    }
    ["function"]=>
    string(12) "require_once"
  }
  [2]=>
  array(4) {
    ["file"]=>
    string(87) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/main.php"
    ["line"]=>
    int(131)
    ["args"]=>
    array(1) {
      [0]=>
      string(103) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/view/template_public.php"
    }
    ["function"]=>
    string(12) "require_once"
  }
  [3]=>
  array(4) {
    ["file"]=>
    string(91) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/public/index.php"
    ["line"]=>
    int(21)
    ["args"]=>
    array(1) {
      [0]=>
      string(87) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/main.php"
    }
    ["function"]=>
    string(12) "require_once"
  }
}

2025-05-09 09:00:19

array(4) {
  [0]=>
  array(4) {
    ["file"]=>
    string(100) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/view/common/debug.php"
    ["line"]=>
    int(37)
    ["function"]=>
    string(1) "p"
    ["args"]=>
    array(1) {
      [0]=>
      array(31) {
        ["head_id"]=>
        string(2) "81"
        ["active"]=>
        string(1) "1"
        ["website"]=>
        string(1) "2"
        ["name"]=>
        string(5) "event"
        ["auth_0"]=>
        string(1) "1"
        ["auth_1"]=>
        string(1) "1"
        ["auth_2"]=>
        string(1) "1"
        ["auth_3"]=>
        string(1) "1"
        ["module"]=>
        string(5) "event"
        ["template"]=>
        string(6) "public"
        ["lang"]=>
        string(2) "en"
        ["url"]=>
        string(3) "all"
        ["route"]=>
        string(1) "2"
        ["class"]=>
        NULL
        ["brand"]=>
        string(1) "1"
        ["title"]=>
        string(10) "our events"
        ["keywords"]=>
        NULL
        ["description"]=>
        NULL
        ["h1"]=>
        string(20) "ISAD Events platform"
        ["h1_subtitle"]=>
        string(16) "Welcome to Doha!"
        ["noindex"]=>
        string(1) "0"
        ["nofollow"]=>
        string(1) "0"
        ["sitemap_pos"]=>
        string(1) "2"
        ["sitemap_title"]=>
        string(10) "All events"
        ["tag"]=>
        array(2) {
          [0]=>
          string(9) ""
          [1]=>
          string(10) ""
        }
        ["action_id"]=>
        string(1) "5"
        ["auth_co"]=>
        string(1) "0"
        ["head"]=>
        string(2) "81"
        ["slug"]=>
        string(3) "all"
        ["event"]=>
        array(40) {
          ["event_id"]=>
          string(1) "8"
          ["active"]=>
          string(1) "1"
          ["public"]=>
          string(1) "1"
          ["website"]=>
          string(1) "2"
          ["pos"]=>
          string(4) "2024"
          ["homepage"]=>
          string(1) "1"
          ["type"]=>
          string(1) "1"
          ["mode"]=>
          string(1) "3"
          ["iteration"]=>
          string(4) "14th"
          ["hash"]=>
          string(13) "rajka2024doha"
          ["url"]=>
          string(20) "rajka-2024-isad-doha"
          ["title"]=>
          string(9) "Doha 2024"
          ["date_display"]=>
          NULL
          ["city"]=>
          string(4) "Doha"
          ["country"]=>
          string(3) "187"
          ["location"]=>
          string(18) "Sheraton Al Majlis"
          ["vintage"]=>
          string(4) "2024"
          ["period_date"]=>
          string(19) "October 24~26, 2024"
          ["period_time"]=>
          NULL
          ["duration"]=>
          NULL
          ["timezone"]=>
          array(9) {
            ["timezone_id"]=>
            string(1) "6"
            ["active"]=>
            string(1) "1"
            ["timezone"]=>
            string(10) "Asia/Qatar"
            ["zone"]=>
            string(6) "Arabia"
            ["abbr"]=>
            string(3) "AST"
            ["utc"]=>
            string(3) "+03"
            ["dateswitch"]=>
            NULL
            ["dateswitch_dst"]=>
            NULL
            ["timeis"]=>
            string(22) "https://time.is/UTC+03"
          }
          ["timeis"]=>
          string(152) "https://time.is/0830_24_Oct_2024_in_Doha/Paris/Zurich/Riga/Berlin/London/Chicago/New_York/Kyoto/S%C3%A3o_Paulo/Riga/Qatar?ISAD-Symposium#google_vignette"
          ["view"]=>
          string(18) "/page/event/common"
          ["description"]=>
          string(376) "Post participation

*The Virtual Portal is open, please click "connect" below:*

* The pre meeting is free for all participants
* The presentations of the symposium are available for registrants, all you need is your ticket number received by email when you registered





➜ Connect"
          ["free"]=>
          NULL
          ["hotmail"]=>
          string(17) "doha2024@isad.org"
          ["dns"]=>
          string(26) "https://doha2024.isad.org/"
          ["brevo_listid"]=>
          string(2) "73"
          ["date_create"]=>
          string(19) "2024-03-22 19:00:00"
          ["date_start"]=>
          string(19) "2024-10-24 00:00:00"
          ["date_deadline"]=>
          string(19) "2024-12-31 23:59:59"
          ["date_stop"]=>
          NULL
          ["date_archive"]=>
          NULL
          ["state"]=>
          string(9) "deadlined"
          ["type_id"]=>
          string(1) "1"
          ["type_title"]=>
          string(20) "Georg RAJKA — ISAD"
          ["auth"]=>
          string(4) "pblc"
          ["fullurl"]=>
          string(30) "/en/event/rajka-2024-isad-doha"
          ["callforabstracts"]=>
          array(0) {
          }
          ["fulltitle"]=>
          string(153) "14th Georg RAJKA — ISAD Doha 2024"
        }
        ["sidebar"]=>
        string(6) "signin"
      }
    }
  }
  [1]=>
  array(4) {
    ["file"]=>
    string(103) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/view/template_public.php"
    ["line"]=>
    int(179)
    ["args"]=>
    array(1) {
      [0]=>
      string(100) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/view/common/debug.php"
    }
    ["function"]=>
    string(12) "require_once"
  }
  [2]=>
  array(4) {
    ["file"]=>
    string(87) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/main.php"
    ["line"]=>
    int(131)
    ["args"]=>
    array(1) {
      [0]=>
      string(103) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/view/template_public.php"
    }
    ["function"]=>
    string(12) "require_once"
  }
  [3]=>
  array(4) {
    ["file"]=>
    string(91) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/public/index.php"
    ["line"]=>
    int(21)
    ["args"]=>
    array(1) {
      [0]=>
      string(87) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/main.php"
    }
    ["function"]=>
    string(12) "require_once"
  }
}

2025-05-09 09:00:19

Array
(
    [body_id] => event
    [body_class] => Array
        (
            [0] => 
        )

    [template] => template_public
    [miseajour] => 2024-10-20
    [assistance] =>  Check our FAQ or contact support@isad.org for assistance
    [vcard] => Array
        (
            [name] => ISAD
            [rcs] => 
            [siret] => 
            [ape] => 
            [capital] => 0
            [immat] => 200x-0x
            [activité] => 
            [categorie] => 
            [forme-juridique] => 
            [dirigeant] => Prof. Alain TAÏEB
            [street-address] => 
            [postal-code] => 
            [locality] => 
            [region] => Grisons
            [country-name] => Switzerland
            [telephone] => 
            [fax] => 
            [email] => support@isad.org
            [google-maps] => https://www.google.com/maps/place/
            [latitude] => 
            [longitude] => 
            [region.geo] => CH-
            [given-name] => Alain
            [family-name] => TAIEB
            [additional-name] => 
            [cnil] => 
            [tva-intra] => 
            [fn-name] => ISAD
            [country-code] => CH
            [hospital] => 
            [chu] => 
        )

    [breadcrumb] => Array
        (
            [0] => Array
                (
                    [url] => 
                    [text] => 
                )

        )

)

array(4) {
  [0]=>
  array(4) {
    ["file"]=>
    string(100) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/view/common/debug.php"
    ["line"]=>
    int(37)
    ["function"]=>
    string(1) "p"
    ["args"]=>
    array(1) {
      [0]=>
      array(7) {
        ["body_id"]=>
        string(5) "event"
        ["body_class"]=>
        array(1) {
          [0]=>
          NULL
        }
        ["template"]=>
        string(15) "template_public"
        ["miseajour"]=>
        string(10) "2024-10-20"
        ["assistance"]=>
        string(200) " Check our FAQ or contact support@isad.org for assistance"
        ["vcard"]=>
        array(31) {
          ["name"]=>
          string(4) "ISAD"
          ["rcs"]=>
          string(0) ""
          ["siret"]=>
          string(0) ""
          ["ape"]=>
          string(0) ""
          ["capital"]=>
          string(1) "0"
          ["immat"]=>
          string(7) "200x-0x"
          ["activité"]=>
          string(0) ""
          ["categorie"]=>
          string(0) ""
          ["forme-juridique"]=>
          string(0) ""
          ["dirigeant"]=>
          string(18) "Prof. Alain TAÏEB"
          ["street-address"]=>
          string(0) ""
          ["postal-code"]=>
          string(0) ""
          ["locality"]=>
          string(0) ""
          ["region"]=>
          string(7) "Grisons"
          ["country-name"]=>
          string(11) "Switzerland"
          ["telephone"]=>
          string(0) ""
          ["fax"]=>
          string(0) ""
          ["email"]=>
          string(16) "support@isad.org"
          ["google-maps"]=>
          string(34) "https://www.google.com/maps/place/"
          ["latitude"]=>
          string(0) ""
          ["longitude"]=>
          string(0) ""
          ["region.geo"]=>
          string(3) "CH-"
          ["given-name"]=>
          string(5) "Alain"
          ["family-name"]=>
          string(5) "TAIEB"
          ["additional-name"]=>
          string(0) ""
          ["cnil"]=>
          string(0) ""
          ["tva-intra"]=>
          string(0) ""
          ["fn-name"]=>
          string(4) "ISAD"
          ["country-code"]=>
          string(2) "CH"
          ["hospital"]=>
          string(0) ""
          ["chu"]=>
          string(0) ""
        }
        ["breadcrumb"]=>
        array(1) {
          [0]=>
          array(2) {
            ["url"]=>
            string(0) ""
            ["text"]=>
            string(26) ""
          }
        }
      }
    }
  }
  [1]=>
  array(4) {
    ["file"]=>
    string(103) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/view/template_public.php"
    ["line"]=>
    int(179)
    ["args"]=>
    array(1) {
      [0]=>
      string(100) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/view/common/debug.php"
    }
    ["function"]=>
    string(12) "require_once"
  }
  [2]=>
  array(4) {
    ["file"]=>
    string(87) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/main.php"
    ["line"]=>
    int(131)
    ["args"]=>
    array(1) {
      [0]=>
      string(103) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/view/template_public.php"
    }
    ["function"]=>
    string(12) "require_once"
  }
  [3]=>
  array(4) {
    ["file"]=>
    string(91) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/public/index.php"
    ["line"]=>
    int(21)
    ["args"]=>
    array(1) {
      [0]=>
      string(87) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/main.php"
    }
    ["function"]=>
    string(12) "require_once"
  }
}

2025-05-09 09:00:19

Array
(
)

array(4) {
  [0]=>
  array(4) {
    ["file"]=>
    string(100) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/view/common/debug.php"
    ["line"]=>
    int(37)
    ["function"]=>
    string(1) "p"
    ["args"]=>
    array(1) {
      [0]=>
      array(0) {
      }
    }
  }
  [1]=>
  array(4) {
    ["file"]=>
    string(103) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/view/template_public.php"
    ["line"]=>
    int(179)
    ["args"]=>
    array(1) {
      [0]=>
      string(100) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/view/common/debug.php"
    }
    ["function"]=>
    string(12) "require_once"
  }
  [2]=>
  array(4) {
    ["file"]=>
    string(87) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/main.php"
    ["line"]=>
    int(131)
    ["args"]=>
    array(1) {
      [0]=>
      string(103) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/view/template_public.php"
    }
    ["function"]=>
    string(12) "require_once"
  }
  [3]=>
  array(4) {
    ["file"]=>
    string(91) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/public/index.php"
    ["line"]=>
    int(21)
    ["args"]=>
    array(1) {
      [0]=>
      string(87) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/main.php"
    }
    ["function"]=>
    string(12) "require_once"
  }
}

2025-05-09 09:00:19

Array
(
    [lang] => en
    [csrf] => Array
        (
            [20250509090019] => 53da535775b95c7fbe6639674ab938805c9bba92232b0bc25c3f0a2ac0910505
        )

)

array(4) {
  [0]=>
  array(4) {
    ["file"]=>
    string(100) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/view/common/debug.php"
    ["line"]=>
    int(37)
    ["function"]=>
    string(1) "p"
    ["args"]=>
    array(1) {
      [0]=>
      array(2) {
        ["lang"]=>
        string(2) "en"
        ["csrf"]=>
        array(1) {
          [20250509090019]=>
          string(64) "53da535775b95c7fbe6639674ab938805c9bba92232b0bc25c3f0a2ac0910505"
        }
      }
    }
  }
  [1]=>
  array(4) {
    ["file"]=>
    string(103) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/view/template_public.php"
    ["line"]=>
    int(179)
    ["args"]=>
    array(1) {
      [0]=>
      string(100) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/view/common/debug.php"
    }
    ["function"]=>
    string(12) "require_once"
  }
  [2]=>
  array(4) {
    ["file"]=>
    string(87) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/main.php"
    ["line"]=>
    int(131)
    ["args"]=>
    array(1) {
      [0]=>
      string(103) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/view/template_public.php"
    }
    ["function"]=>
    string(12) "require_once"
  }
  [3]=>
  array(4) {
    ["file"]=>
    string(91) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/public/index.php"
    ["line"]=>
    int(21)
    ["args"]=>
    array(1) {
      [0]=>
      string(87) "/home/clients/717e994bc3f18278ed6c5a387092d949/vhost/isad.org/platform/dev/APP/main.php"
    }
    ["function"]=>
    string(12) "require_once"
  }
}

ISAD Events platform

Doha 2024 Georg RAJKA — ISAD Sheraton Al Majlis October 24~26, 2024

Post participation

Post participation

Doha 2024
Georg RAJKA — ISAD
Sheraton Al Majlis
October 24~26, 2024